Long Term Treatment With L-DOPS

Vanderbilt University

Status

Conditions: Dopamine Beta Hydroxylase (DBH) Deficiency

Treatments: Drug: droxidopa

Study type: Expanded Access

Funder types: Other

Identifiers

NCT00889135

041037

Details and patient eligibility

About

This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years old or older with orthostatic hypotension
• established diagnosis of DBH deficiency and fractionated plasma catecholamine levels that show high dopamine levels and very low norepinephrine and epinephrine levels. Blood pressure increase in response to oral treatment with L-DOPS during previous studies.

Exclusion criteria

• subjects with orthostatic hypotension that do not have a genetic form of the disorder and catecholamine pattern is not consistent with that above.